InMed Pharmaceuticals (INM) EBIAT: 2021-2025
Historic EBIAT for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -$1.7 million.
- InMed Pharmaceuticals' EBIAT fell 1.58% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.2 million, marking a year-over-year decrease of 19.81%. This contributed to the annual value of -$8.2 million for FY2025, which is 6.49% down from last year.
- Latest data reveals that InMed Pharmaceuticals reported EBIAT of -$1.7 million as of Q3 2025, which was up 4.06% from -$1.8 million recorded in Q2 2025.
- In the past 5 years, InMed Pharmaceuticals' EBIAT ranged from a high of -$338,391 in Q2 2023 and a low of -$7.9 million during Q2 2022.
- Over the past 3 years, InMed Pharmaceuticals' median EBIAT value was -$1.8 million (recorded in 2025), while the average stood at -$1.8 million.
- Its EBIAT has fluctuated over the past 5 years, first soared by 95.70% in 2023, then slumped by 479.84% in 2024.
- InMed Pharmaceuticals' EBIAT (Quarterly) stood at -$3.0 million in 2021, then grew by 29.29% to -$2.1 million in 2022, then increased by 29.65% to -$1.5 million in 2023, then crashed by 74.20% to -$2.6 million in 2024, then declined by 1.58% to -$1.7 million in 2025.
- Its EBIAT stands at -$1.7 million for Q3 2025, versus -$1.8 million for Q2 2025 and -$2.1 million for Q1 2025.